Medtech OEMs Face a Rare but Closing Window of Opportunity

Why It Matters

Timing is critical: early, well‑prepared moves can lock in premium valuations, while hesitation risks losing strategic advantage and higher costs.

Key Takeaways

• CDMO market reached $91B in 2024, driven by complexity
• 2025 CDMO M&A value hit $22B, indicating rebound
• Specialized manufacturing assets command premium valuations
• OEMs must choose divestiture or acquisition before 2026
• Deal readiness boosts multiples, reduces transaction friction

Pulse Analysis

The medtech manufacturing landscape is undergoing a structural reset, with original equipment manufacturers confronting unprecedented pressure to modernize. As devices blend hardware and software, legacy factories struggle to meet regulatory and technical demands, pushing OEMs toward contract development and manufacturing organizations (CDMOs) that specialize in high‑complexity production. This shift has propelled the global CDMO market from $73 billion in 2022 to $91 billion in 2024, creating a fertile environment for strategic partnerships and asset sales.

Deal activity in 2025 underscores the momentum: CDMO transactions surged to $22 billion, and a marquee $1.5 billion sale of a medical OEM division set a new valuation benchmark for specialized platforms. Buyers are prioritizing entire capabilities over single projects, rewarding companies that have streamlined cost structures, documented processes, and achieved regulatory compliance such as MDSAP and MDR. Consequently, OEMs that have pre‑pared their non‑core assets can extract top‑of‑the‑range multiples, while those seeking acquisitions can secure capabilities that would otherwise require years of internal development.

For OEM leadership, the imperative is clear: act decisively in 2026 or risk being priced out of the market. A disciplined portfolio‑optimization approach—identifying core competencies, divesting peripheral lines, and targeting strategic acquisitions—will safeguard competitive advantage. Delaying the decision not only erodes valuation leverage but also cedes ground to rivals ready to move. Companies that align their R&D roadmap with manufacturing strategy and execute with rigor will emerge stronger in the evolving medtech ecosystem.